TITLE

A Microsimulation of the Cost-effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-Infected Individuals

AUTHOR(S)
Kühne, Felicitas C.; Chancellor, Jeremy; Mollon, Patrick; Myers, Daniela E.; Louie, Michael; Powderly, William G.
PUB. DATE
March 2010
SOURCE
HIV Clinical Trials;Mar/Apr2010, Vol. 11 Issue 2, p80
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: Maraviroc (MVC) is the first approved CCR5 antagonist. The aim of this study was to explore the cost-effectiveness of MVC in treatment-experienced or treatment-resistant HIV-infected adults.Methods: The validated HIV microsimulation model ARAMIS was used to predict clinical and economic outcomes of treating patients with optimized background therapy (OBT) alone, as compared to a strategy of testing for the patient's viral tropism and treating with OBT with or without (±) MVC in a cohort corresponding to the MOTIVATE screening cohort.Results: Compared to treatment with OBT alone, a treatment strategy of OBT ± MVC (twice daily) according to tropism test result was predicted to increase CD4+ cell count after 5 years (from mean 249 to 360 cells/μL), undiscounted life expectancy (7.6 to 8.9 years), and quality-adjusted life years (QALYs; from 4.99 to 5.71) for an additional $40,500, giving an incremental cost-effectiveness ratio of $56,400 per QALY gained. The result was relatively insensitive to alternative clinical and cost assumptions within reasonable ranges, but for individuals with HIV susceptible to only two or fewer components of OBT, the ICER decreased to $52,000 per QALY gained.Conclusion: MVC is cost-effective, especially among individuals with few remaining options for active antiretroviral therapy.
ACCESSION #
56944974

 

Related Articles

  • Immune recovery among HIV-infected patients in northwestern Tanzania after 2 years of anti-retroviral therapy use: a retrospective cohort study. MPONDO, BONAVENTURA C. T.; KABANGILA, RODRICK; EPHRAIM, LUCHERI; ERNEST, ALEX; KIDENYA, BENSON R. // Tanzania Journal of Health Research;Oct2015, Vol. 17 Issue 4, p1 

    Background: The use of antiretroviral therapy (ART) for the treatment of human immunodeficiency virus (HIV) is associated with significant and sustained decrease in the viral RNA levels that allows the immune system to recover. The extent of this immune recovery depends on the baseline CD4...

  • Five-Year Outcomes of the China National Free Antiretroviral Treatment Program.  // Annals of Internal Medicine;8/18/2009, Vol. 151 Issue 4, pI-42 

    The article presents a study on the rate of recovery of patients in the National Free Antiretroviral Treatment Program in China after five years. It notes that 48,785 patients with HIV were enrolled in the program under the highly active antiretroviral therapy. It mentions that after 6 months of...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Oct2005, Vol. 19 Issue 10, p696 

    Reports several developments related to antiviral agents worldwide. Accounts on the reaction of HIV viral load to ritonavir-boosted atazanavir used as monotherapy; Analysis by Great Britain researchers on the benefit of highly active antiretroviral therapy when compared to no treatment in...

  • Oral Lesions of HIV Disease and HAART in Industrialized Countries. Hodgson, T. A.; Greenspan, D.; Greenspan, J. S. // Advances in Dental Research;Apr2006, Vol. 19 Issue 1, p57 

    The epidemiology of HIV-related oral disease in industrialized nations has evolved following the initial manifestations described in 1982. Studies from both the Americas and Europe report a decreased frequency of HIV-related oral manifestations of 10-50% following the introduction of HAART...

  • Normalization of B Cell Counts and Subpopulations after Antiretroviral Therapy in Chronic HIV Disease. Moir, Susan; Malaspina, Angela; Ho, Jason; Wei Wang; DiPoto, Angela C.; O'Shea, Marie A.; Roby, Gregg; Mican, Joann M.; Kottilil, Shyam; Tae-Wook Chun; Proschan, Michael A.; Fauci, Anthony S. // Journal of Infectious Diseases;2/15/2008, Vol. 197 Issue 4, p572 

    Background. Untreated human immunodeficiency virus (HIV) disease leads to abnormalities in all major lymphocyte populations, including CD4+ T cells, CD8+ T cells, and B cells. However, little is known regarding the effect of antiretroviral therapy (ART)-induced decrease in HIV viremia on B cell...

  • The Safety and Efficacy of Enfuvirtide Therapy for HIV Infection in Patients with Hemophilia: A Case Series. Polizzotto, Mark N.; Street, Alison M.; Wright, Edwina // Clinical Infectious Diseases;8/15/2007, Vol. 45 Issue 4, pe39 

    The treatment of patients with human immmunodeficiency virus (HIV) infection and hemophilia involves unique challenges that may be addressed with novel antiretroviral classes. We describe the safety and efficacy of enfuvirtide therapy in 4 patients with severe hemophilia A. Although local skin...

  • Safety Profi le of Maraviroc in Patients Coinfected With HIV-1 and Hepatitis B or C Included in the Maraviroc Expanded Access Program. Lazzarin, Adriano; Than, Soe; Valluri, Srinivas R.; Heera, Jayvant; Mukwaya, Geoffrey // HIV Clinical Trials;Mar/Apr2012, Vol. 13 Issue 2, p83 

    Objective: To evaluate the safety of maraviroc with other antiretrovirals in patients with HIV-1 coinfected with hepatitis B virus (HBV) or hepatitis C virus (HCV).Methods: This was a multicenter, noncomparative, open-label, expanded access program (EAP) initiated in February 2007. Patients with...

  • Delayed Progression to Death and to AIDS in a Hong Kong Cohort of Patients with Advanced HIV Type 1 Disease During the Era of Highly Active Antiretroviral Therapy. Ka Hing Wong; Kenny Chi Wai Chan; Shui Shan Lee // Clinical Infectious Diseases;9/15/2004, Vol. 39 Issue 6, p853 

    Background. The magnitude of the impact of highly active antiretroviral therapy (HAART) since its introduction in non-Western countries is not entirely clear. We studied disease progression among adult patients with advanced human immunodeficiency virus type 1 (HIV-1) infection in the pre-HAART...

  • Treatment of Mycobacterium avium Complex Immune Reconstitution Disease in HIV-1-Infected Individuals. Desimone, Joseph A.; Babinchak, Timothy J.; Kaulback, Kris R.; Pomerantz, Roger J. // AIDS Patient Care & STDs;Dec2003, Vol. 17 Issue 12, p617 

    Immune reconstitution disease caused by Mycobacterium avium complex (MAC) infection presenting shortly after the introduction of highly active antiretroviral therapy (HAART) has been reported with increasing frequency in persons with HIV-1 infection during the past several years. Several...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics